Alphyn completes trial enrollment

Alphyn Biologics, a clinical-stage dermatology company, has successfully completed patient enrollment for its Phase 2 trial of a topical therapy for molluscum contagiosum. This milestone is a significant step forward in the development of the company's novel Multi-Target Therapeutics® drug platform. The trial will evaluate the efficacy and safety of the topical treatment for this common skin condition. Successful completion of enrollment paves the way for data analysis and potential progression to later-stage trials.